Announcements
- Pharming Group to report first quarter 2024 financial results on May 8
- Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
- Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025
- Pharming Group announces the placement of €100 million convertible bonds due 2029
- Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
- Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
- Pharming Group announces the 2024 Annual General Meeting of Shareholders
- Pharming Group announces the filing of its 2023 Annual Report and Form 20-F
- Pharming Group to participate in April investor conferences
- Pharming Group reports fourth quarter and full year 2023 financial results
More ▼
Key statistics
As of last trade Pharming Group NV (0QCO:LSE) traded at 0.893, 3.60% above its 52-week low of 0.862, set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.8903 |
---|---|
High | -- |
Low | -- |
Bid | 0.868 |
Offer | 0.9125 |
Previous close | 0.88 |
Average volume | 1.30m |
---|---|
Shares outstanding | 671.07m |
Free float | 655.38m |
P/E (TTM) | -- |
Market cap | 589.45m EUR |
EPS (TTM) | -0.0162 EUR |
Data delayed at least 20 minutes, as of Apr 26 2024 11:14 BST.
More ▼